Work

Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute myeloid leukemia.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.7030

Authors: Olatoyosi Odenike, Johannes E. Wolff, Gautam Borthakur, Ibrahim Taha Aldoss, David Rizzieri, Thomas Prebet, Beibei Hu, Minh Dinh, Xiaotian Chen, Dimple Modi, Kevin J Freise, Brian Andrew Jonas

Institutions: University of Chicago Medical Center, AbbVie (United States), The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, Duke University, Duke Medical Center, Yale New Haven Hospital, Yale University, UC Davis Comprehensive Cancer Center

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2960223965

Cites:

Cited by: 19

Related to: 10